We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

No hostile to hostile

4 Oct 2010 By Pierre Briancon

The French pharma group is taking its rebuffed $69ashare offer directly to the U.S. biotech’s shareholders. This shows Sanofi’s confidence that it can clinch a deal, and worry that waiting will make its target more expensive. But a sweeter offer is still more than likely.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)